ATE500808T1 - Onkolytische virustherapie - Google Patents

Onkolytische virustherapie

Info

Publication number
ATE500808T1
ATE500808T1 AT02725980T AT02725980T ATE500808T1 AT E500808 T1 ATE500808 T1 AT E500808T1 AT 02725980 T AT02725980 T AT 02725980T AT 02725980 T AT02725980 T AT 02725980T AT E500808 T1 ATE500808 T1 AT E500808T1
Authority
AT
Austria
Prior art keywords
oncolytic virus
pharmaceutical composition
virus therapy
subject
human leukocytes
Prior art date
Application number
AT02725980T
Other languages
English (en)
Inventor
William Groene
Jeffrey Miller
Stephen Mueller
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ATE500808T1 publication Critical patent/ATE500808T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02725980T 2001-05-11 2002-05-09 Onkolytische virustherapie ATE500808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29005101P 2001-05-11 2001-05-11
PCT/US2002/014642 WO2002091997A2 (en) 2001-05-11 2002-05-09 Oncolytic virus therapy

Publications (1)

Publication Number Publication Date
ATE500808T1 true ATE500808T1 (de) 2011-03-15

Family

ID=23114328

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725980T ATE500808T1 (de) 2001-05-11 2002-05-09 Onkolytische virustherapie

Country Status (13)

Country Link
US (3) US7122182B2 (de)
EP (1) EP1385466B1 (de)
JP (1) JP4916641B2 (de)
CN (1) CN1332712C (de)
AT (1) ATE500808T1 (de)
AU (1) AU2002256510B2 (de)
CA (1) CA2442648C (de)
DE (1) DE60239394D1 (de)
HU (1) HUP0400882A3 (de)
IL (1) IL157504A0 (de)
MX (1) MXPA03010278A (de)
NZ (1) NZ527687A (de)
WO (1) WO2002091997A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
IL157504A0 (en) 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20050214266A1 (en) * 2004-03-12 2005-09-29 Oncolytics Biotech Inc. Combination of transplantation and oncolytic virus treatment
EP1793851B1 (de) * 2004-08-20 2016-10-05 Viralytics Limited Verfahren und zusammensetzungen zur behandlung von blutkrebs
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20070077231A1 (en) * 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
WO2008009115A1 (en) * 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
WO2009067808A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
WO2010020247A1 (en) * 2008-08-22 2010-02-25 Reapplix Aps Multilayered blood product
WO2010080909A1 (en) * 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EP4219457A1 (de) 2015-01-26 2023-08-02 Ottawa Hospital Research Institute 3-(2h)-pyridazinone derivate, deren zusammensetzungen und verfahren zur virussensibilisierung
GB201504251D0 (en) 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
KR20180108649A (ko) 2016-01-06 2018-10-04 레아플릭스 에이피에스 차후의 자가 사용을 위한 응혈 촉진 인자
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
EP3491013A1 (de) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155-variante immunmodulatorische proteine und verwendungen davon
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN110022889B (zh) 2016-10-03 2024-05-10 渥太华医院研究所 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CA3052473A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
EP3596114A2 (de) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80-variante immunmodulatorische proteine und verwendungen davon
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
AU2018373508A1 (en) 2017-11-24 2020-04-30 Ottawa Hospital Research Institute Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CA3177467A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN113271955A (zh) 2018-11-06 2021-08-17 卡利迪生物治疗有限公司 用于细胞介导的溶瘤病毒疗法的增强的系统
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3131017C (en) 2019-02-27 2025-05-13 Actym Therapeutics, Inc. Immunostimulatory bacteria modified to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
CN117379389B (zh) * 2022-07-12 2026-03-06 四川大学 血小板-溶瘤病毒复合物、其制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
PT696326E (pt) * 1993-04-30 2003-08-29 Wellstat Biologics Corp Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
DE69718029T2 (de) * 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
NZ503664A (en) 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
US6177076B1 (en) * 1997-12-09 2001-01-23 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
NZ550861A (en) * 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
JP3639772B2 (ja) * 1999-06-30 2005-04-20 キヤノン株式会社 情報処理装置および印刷システムおよび印刷制御方法およびコンピュータが読み出し可能なプログラムを格納した記憶媒体
DE60041210D1 (de) 1999-09-17 2009-02-05 Wellstat Biologics Corp Onkolytisches Virus
US6270147B1 (en) * 2000-01-07 2001-08-07 Daimlerchrysler Corporation Drive arrangement for a power liftgate including clutching mechanism
CN1250711C (zh) * 2000-06-26 2006-04-12 威尔斯达特生物制剂公司 用病毒清除细胞
IL157504A0 (en) * 2001-05-11 2004-03-28 Wellstat Biologics Corp Oncolytic virus therapy

Also Published As

Publication number Publication date
JP4916641B2 (ja) 2012-04-18
US7595042B2 (en) 2009-09-29
US20090180994A1 (en) 2009-07-16
EP1385466B1 (de) 2011-03-09
HUP0400882A2 (hu) 2004-07-28
DE60239394D1 (de) 2011-04-21
JP2004521938A (ja) 2004-07-22
MXPA03010278A (es) 2004-12-06
CN1514688A (zh) 2004-07-21
IL157504A0 (en) 2004-03-28
US8137663B2 (en) 2012-03-20
AU2002256510B2 (en) 2007-08-30
EP1385466A4 (de) 2005-10-12
CN1332712C (zh) 2007-08-22
WO2002091997A2 (en) 2002-11-21
NZ527687A (en) 2005-10-28
WO2002091997A3 (en) 2003-03-13
CA2442648C (en) 2012-10-16
CA2442648A1 (en) 2002-11-21
EP1385466A2 (de) 2004-02-04
US20030077819A1 (en) 2003-04-24
HUP0400882A3 (en) 2011-01-28
US20050208024A1 (en) 2005-09-22
US7122182B2 (en) 2006-10-17

Similar Documents

Publication Publication Date Title
DE60239394D1 (de) Onkolytische virustherapie
NO20026044D0 (no) Behandling av human papillomavirus
ES2187798T3 (es) Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento.
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
DE60041210D1 (de) Onkolytisches Virus
DK184186A (da) Terapeutisk praeparat til behandling af virussygdomme
MY117892A (en) Therapeutic compounds
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
GEP20053504B (en) Low Dose Entecavir Pharmaceutical Composition and Use Thereof for Treatment of Hepatitis B
AP9801286A0 (en) Therapeutic compounds.
MD990258A (en) Method of treatment of the acute viral hepatitis B
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
MXPA04001912A (es) Aminobenzofenonas novedosas.
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
WO2001070951A3 (de) Mittel zur diagnose und therapie viraler erkrankungen
DE69925312D1 (de) Bupropion zur behandlung von viralen erkrankungen
DK1150981T3 (da) Terapeutisk necleosidforbindelse
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
TW200513258A (en) Auxiliary agent for hepatitis C
SU1565027A1 (ru) Инактиватор вируса западного нила
ITAG940002A0 (it) Apparecchio ossigenatore e purificatore del sangue infetto da virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties